title: Results of two different conditioning regimens followed by ABMT in refractory acute lymphoblastic leukemia.
abstract: Thirty-one patients affected by advanced ALL entered this study. Twenty (1 in I CR, 9 in II CR, 6 in III CR and 4 extramedullary relapses) were treated with the BMVC conditioning regimen. Eleven (9 in II CR, 2 in III CR) received the Busulfan plus Cytoxan conditioning regimen. Asta-Z 7654-purged marrow was reinfused at day 0. Both protocols were well tolerated. Two patients treated with the BMVC regimen died in aplasia from sepsis; 1 patient died in CR 5 months after transplantation, 13 relapsed after a median time of 4 months (range 1-31). Four patients are in CCR with a median follow-up of 16 months (range 11-24). In the BU + CY treated group no toxic deaths were observed. Four patients relapsed after a median of 3 months (range 2-7) and 7 are in CCR with a median follow-up of 5 months (range 2-28).
authors.forename: G
authors.initials: G
authors.lastname: Meloni
authors.forename: P
authors.initials: P
authors.lastname: De Fabritiis
authors.forename: A
authors.initials: A
authors.lastname: Pulsoni
authors.forename: A
authors.initials: A
authors.lastname: Sandrelli
authors.forename: F
authors.initials: F
authors.lastname: Giona
authors.forename: F
authors.initials: F
authors.lastname: Simone
authors.forename: F
authors.initials: F
authors.lastname: Mandelli
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D002066:Busulfan / Q000008:administration & dosage; D002330:Carmustine / Q000008:administration & dosage / Q000627:therapeutic use; D002648:Child; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology; D003561:Cytarabine / Q000008:administration & dosage / Q000627:therapeutic use; D004351:Drug Resistance; D005047:Etoposide / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008942:Mitoxantrone / Q000008:administration & dosage / Q000627:therapeutic use; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy / Q000601:surgery*; D011300:Preoperative Care / Q000379:methods*; D014182:Transplantation, Autologous
chemical_list: D003561:Cytarabine; D005047:Etoposide; D003520:Cyclophosphamide; C047251:mafosfamide-lysine; D008942:Mitoxantrone; D002066:Busulfan; D002330:Carmustine